FDA Approves Bristol-Myers, AstraZeneca Diabetes Drug

Law360, Washington (January 8, 2014, 4:05 PM EST) -- The U.S. Food and Drug Administration on Wednesday approved a Bristol-Myers Squibb Co. and AstraZeneca Pharmaceuticals LP drug designed to treat Type 2 diabetes, about one year after rejecting the same drug due to its potential link to bladder cancer.

The agency said in a news release that it had approved Farxiga, known generically as dapagliflozin, which improves glycemic control with diet and exercise for adults with Type 2 diabetes.

“Controlling blood sugar levels is very important in the overall treatment and care of diabetes, and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.